U.S. markets closed

22nd Century Group, Inc. (XXII)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
2.4000+0.2200 (+10.09%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.1800
Open2.2600
Bid2.4100 x 1100
Ask2.4000 x 3100
Day's Range1.8600 - 2.4000
52 Week Range0.5500 - 4.6600
Volume6,193,149
Avg. Volume3,970,796
Market Cap333.262M
Beta (5Y Monthly)1.61
PE Ratio (TTM)N/A
EPS (TTM)-0.1430
Earnings DateMar 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 22nd Century Group to Participate in Investor Conferences in March 2021
    GlobeNewswire

    22nd Century Group to Participate in Investor Conferences in March 2021

    WILLIAMSVILLE, N.Y., March 05, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, today announced that members of its management team will participate in three investor conferences during March 2021. Institutional investors and those invited to attend these virtual conference events may request one-on-one meetings with representatives of the Company through the respective conference hosts or by contacting 22nd Century Group’s investor relations via mkuo@xxiicentury.com. Events 22nd Century Group will participate in include: The DA Davidson 4th Annual Consumer Growth Conference, March 11, 2021One-on-one meetings will be available on the afternoon of Thursday, March 11. To request a meeting, please contact your DA Davidson sales representative. The 33rd Annual Roth Conference, March 15-17, 2021One-on-one and small group meetings will be available on Tuesday, March 16. Additional times may be available to accommodate meeting requests as needed. To request a meeting, please contact your Roth sales representative. The Investor Summit Virtual Conference, March 23-25, 2021James A. Mish, chief executive officer of 22nd Century, will provide an overview presentation of the Company. An audio webcast of the presentation will be available through 22nd Century’s Events web page in the Company's Investor Relations section of the website, at www.xxiicentury.com/investors/events. One-on-one meetings will be available on Tuesday, March 23. To request a meeting, please contact your Investor Summit Group representative. About 22nd Century Group, Inc.22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding. 22nd Century’s primary mission in tobacco is to reduce the harm caused by smoking through the Company’s proprietary reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes. The Company’s primary mission in hemp/cannabis is to develop and commercialize proprietary hemp/cannabis plants with valuable cannabinoid profiles and desirable agronomic traits. Learn more at xxiicentury.com, on Twitter @_xxiicentury, and on LinkedIn. Cautionary Note Regarding Forward-Looking StatementsExcept for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 11, 2020, and in its subsequently filed Quarterly Report on Form 10-Q. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law. Investor Relations & Media Contact:Mei KuoDirector, Communications & Investor Relations22nd Century Group, Inc.(716) 300-1221mkuo@xxiicentury.com

  • Will 22nd Century Group (XXII) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will 22nd Century Group (XXII) Report Negative Earnings Next Week? What You Should Know

    22nd Century (XXII) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • 22nd Century Group Receives $8.1 Million from Cash Exercise of Outstanding Warrants
    GlobeNewswire

    22nd Century Group Receives $8.1 Million from Cash Exercise of Outstanding Warrants

    WILLIAMSVILLE, N.Y., March 04, 2021 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a leading plant-based, biotechnology company focused on tobacco harm reduction, very low nicotine content tobacco, and hemp/cannabis research, today announced that it has received net proceeds of $8.1 million from the cash exercise of outstanding warrants during February and March of 2021. The remaining warrants, if exercised for cash, will bring additional net proceeds of $3.7 million in cash to the Company. Following the above transaction, the Company will no longer have any outstanding warrants. “We are pleased to further strengthen our balance sheet with $8.1 million from the exercise of these existing warrants that were already a consideration in our fully diluted capital structure,” said James A. Mish, chief executive officer of 22nd Century Group. “The capital will provide us with additional runway to further fuel our current operations, strategy, and growth initiatives including near-term opportunities in both our tobacco and hemp/cannabis franchises. We look forward to securing Modified Risk Tobacco Products (MRTP) authorization, launching VLN®, and building the VLN® brand. The additional cash will also support our hemp/cannabis R&D initiatives and the development of our third franchise in 2021.” About 22nd Century Group, Inc.22nd Century Group, Inc. (NYSE American: XXII) is a leading plant biotechnology company focused on technologies that alter the level of nicotine in tobacco plants and the level of cannabinoids in hemp/cannabis plants through genetic engineering, gene-editing, and modern plant breeding. 22nd Century’s primary mission in tobacco is to reduce the harm caused by smoking through the Company’s proprietary reduced nicotine content tobacco cigarettes – containing 95% less nicotine than conventional cigarettes. The Company’s primary mission in hemp/cannabis is to develop and commercialize proprietary hemp/cannabis plants with valuable cannabinoid profiles and desirable agronomic traits. Learn more at xxiicentury.com, on Twitter @_xxiicentury, and on LinkedIn. Cautionary Note Regarding Forward-Looking StatementsExcept for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements typically contain terms such as “anticipate,” “believe,” “consider,” “continue,” “could,” “estimate,” “expect,” “explore,” “foresee,” “goal,” “guidance,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “preliminary,” “probable,” “project,” “promising,” “seek,” “should,” “will,” “would,” and similar expressions. Actual results might differ materially from those explicit or implicit in forward-looking statements. Important factors that could cause actual results to differ materially are set forth in “Risk Factors” in the Company’s Annual Report on Form 10-K filed on March 11, 2020, and in its subsequently filed Quarterly Report on Form 10-Q. All information provided in this release is as of the date hereof, and the Company assumes no obligation to and does not intend to update these forward-looking statements, except as required by law. Investor Relations & Media Contact:Mei KuoDirector, Communications & Investor Relations22nd Century Group, Inc.(716) 300-1221mkuo@xxiicentury.com